The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing.
The San Diego drug developer said late Monday that the typically routine step of ratifying the company’s auditor failed a shareholder vote. Arcturus (NASDAQ: ARCT) blamed the failure on Joseph Payne, who was fired as CEO on Feb. 1. Though Payne no longer works for Arcturus, he still owns 13.7 percent of the company’s shares and sits on its board of directors.
Arcturus says Payne and others… Read more »
UNDERWRITERS AND PARTNERS